Probo Medical Acquires Canute Medical

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of Canute Medical (“Canute”). Terms of the transaction were not disclosed.

Canute, incorporated in 2012, is a leading service provider for installation, de-installation, removals, and remarketing of pre-owned medical equipment such as MRI, CT, X-Ray and Gamma Cameras for clients around the world. Based in Oakville, Ontario, Canute is led today by Ben Rice and supported by a team of medical equipment professionals with a deep understanding of the large imaging equipment markets.

“We’re fortunate to have Ben and his team at Canute join the Probo family as they will add tremendous expertise to our team,” said Michael Asmer, CEO of Probo Medical. “With this expansion, we look forward to growing our presence in Canada with a recognized team in the industry.”

Ben Rice, Director of Canute Medical, “Aligning with Probo connects the Canute team to a platform that will enhance our services for customers. We see a great opportunity ahead for the expansion of the solutions we can bring to the market.”

Probo Medical is backed by Avista Capital Partners, a leading New York-based private equity firm with more than 40 growth-oriented healthcare businesses globally.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.